Before November 15, 2028, noteholders will have the right to convert their notes only upon the occurrence of certain events. The notes will mature on February 15, 2029, unless earlier repurchased, redeemed or converted. The notes will be senior, unsecured obligations of Collegium and will accrue interest at a rate of 2.875% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2023. The sale of the notes to the initial purchasers is expected to settle on February 10, 2023, subject to customary closing conditions. Collegium also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $31,500,000 principal amount of notes. The offering was upsized from the previously announced offering size of $175,000,000 aggregate principal amount of notes. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

07, 2023 (GLOBE NEWSWIRE) - Collegium Pharmaceutical, Inc.

Signed mass effect redemption